Alternative Immunization Strategies For Smallpox

天花的替代免疫策略

• 批准号: 7184283
• 负责人: Barney Scott Graham
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7184283
• 关键词: antibody formation; antiviral antibody; attenuated microorganism; biological models; bioterrorism /chemical warfare; cytotoxic T lymphocyte; drug administration routes; helper T lymphocyte; human tissue; immunization; immunocytochemistry; inhalation drug administration; injection /infusion; laboratory mouse; live vaccine; recombinant virus; smallpox vaccine; vaccine evaluation; vaccinia virus

The current licensed vaccine against smallpox, Dryvax?, generates strong and long-lasting immunity. However, serious side-effects are associated with Dryvax? immunization. Furthermore, in the current environment of a naive population and with an increasing number of immunocompromised people, use of the replication-competent Dryvax? immunogen may be considered ill-advised. In the current political situations, the threat also exists of a weaponized form of the smallpox virus. The goal of these studies is to evaluate the efficacy of the non-replicating vaccinia virus MVA (modified vaccinia Ankara) in protecting against challenge with replication-competent vaccinia virus. The correlates of immunity induced by Dryvax? immunization have not been identified. Therefore, these studies will evaluate the contributions of CD4+ T cells, CD8+ T cells, and antibody to anti-vaccinia virus immunity.

当前针对天花的许可疫苗Dryvax？，可产生强大而持久的免疫力。但是，严重的副作用与Dryvax有关吗？免疫。此外，在当前天真人口的环境中，使用了竞争能力的Dryvax的人数越来越多的免疫功能低下的人？免疫原可能被认为是不明智的。在当前的政治情况下，威胁也存在天花病毒的武器形式。这些研究的目的是评估非复制疫苗病毒MVA（修饰的vaccinia ankara）在防止复制能竞争性疫苗病毒的挑战方面的疗效。 Dryvax诱导的免疫力的相关性？尚未确定免疫。因此，这些研究将评估CD4+ T细胞，CD8+ T细胞的贡献以及抗体对抗Vaccinia病毒免疫的贡献。